Summary: The paper discusses the latest EAACI/GA2LEN/EDF/WAO guidelines on the definition, classification, diagnosis and treatment of urticaria. Urticaria is a heterogeneous disease that significantly interferes with life activity and reduces patients' quality of life. The aim of treatment is full control of symptoms, taking into account the safety of the applied therapies and improving quality of life.
Therefore, in the management of urticaria an attempt should be made to identify and eliminate causal factors, and symptomatic treatment applied. Non-sedating second-generation antihistamines are recommended as the first-line treatment in urticaria, regardless of its subtype. In the second-line therapy it is recommended to use higher, even fourfold, daily doses of second-generation antihistamines due to the high effectiveness and confirmed safety of such treatments. In the third-line therapy, experts recommend the use of omalizumab as an add-on therapy to the previous treatment. The use of cyclosporin A has a lower strength of recommendation.